https://www.healthwireeasttimor.com/article/914627424-heallexa-launches-ai-powered-healthcare-directory-with-over-6-million-provider-profiles-to-make-finding-and-booking-care-more-convenient Health Wire East Timor en PressRelease 2026-05-23T13:31:00+00:00 Heallexa Launches AI Powered Healthcare Directory With Over 6 Million Provider Profiles to Make Finding and Booking Care More Convenient https://pressranger.s3.us-west-1.amazonaws.com/3309426/HL.png https://www.healthwireeasttimor.com/article/914548444-dempster-therapeutic-services-launches-chicago-speech-therapy-and-polski-logopeda-digital-storefronts-with-instant-online-booking-patient-portal Health Wire East Timor en PressRelease 2026-05-23T04:48:00+00:00 Dempster Therapeutic Services Launches “Chicago Speech Therapy” And “Polski logopeda” Digital Storefronts With Instant Online Booking, Patient Portal, And Rapid Access To Award-Winning Speech Therapy Services https://pressranger.s3.us-west-1.amazonaws.com/3307140/ZocDoc-Award-2026-BRANDED.png https://www.healthwireeasttimor.com/article/914491699-roota-hair-growth-roll-on-scalp-serum-roota-hair-activator-spray-under-investigation-evaluating-the-clinically-tested-hair-care-formula-s-claims Health Wire East Timor en PressRelease 2026-05-23T00:33:12+00:00 Roota Hair Growth Roll-On Scalp Serum & Roota Hair Activator Spray Under Investigation: Evaluating the Clinically-Tested Hair Care Formula's Claims https://zingfast.com/wp-content/uploads/2026/05/Roota-Hair-Growth-Roll-On-Scalp-Serum.jpg https://www.healthwireeasttimor.com/article/914473691-organifi-parasite-cleanse-kit-the-most-effective-herbal-parasite-binding-detox-supplements-on-the-market Health Wire East Timor en PressRelease 2026-05-22T22:55:19+00:00 Organifi Parasite Cleanse Kit: The Most Effective Herbal Parasite Binding Detox Supplements on the Market https://zingfast.com/wp-content/uploads/2026/05/Organifi-Parasite-Cleanse-Kit.jpg https://www.healthwireeasttimor.com/article/914464327-slim-tide-under-investigation-critical-research-details-ingredients-effectiveness-for-metabolic-digestive-support Health Wire East Timor en PressRelease 2026-05-22T22:18:30+00:00 Slim Tide Under Investigation: Critical Research Details Ingredients' Effectiveness for Metabolic & Digestive Support https://zingfast.com/wp-content/uploads/2026/05/Slim-Tide-1.jpg https://www.healthwireeasttimor.com/article/914455337-calidi-biotherapeutics-provides-required-nyse-american-disclosure Health Wire East Timor en PressRelease 2026-05-22T22:00:00+00:00 Calidi Biotherapeutics Provides Required NYSE American Disclosure https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.healthwireeasttimor.com/article/914455361-glycopulse-claims-evaluated-most-advanced-blood-sugar-support-ingredients-for-healthy-glucose-management-by-glyco-pulse Health Wire East Timor en PressRelease 2026-05-22T21:41:39+00:00 GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse https://zingfast.com/wp-content/uploads/2026/05/GlycoPulse.jpg https://www.healthwireeasttimor.com/article/914446110-iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Wire East Timor en PressRelease 2026-05-22T21:15:00+00:00 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d0986bd6-4603-4e31-8ed1-f23b3e123605/small/iovance-jpg.jpg https://www.healthwireeasttimor.com/article/914446172-immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-stock Health Wire East Timor en PressRelease 2026-05-22T21:15:00+00:00 Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png https://www.healthwireeasttimor.com/article/914437208-ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Health Wire East Timor en PressRelease 2026-05-22T20:30:00+00:00 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/121a9bda-7a64-41f8-85e8-1693a2dfa977/small/ultragenyx-cmyk-png.png https://www.healthwireeasttimor.com/article/914437221-greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-q-filing Health Wire East Timor en PressRelease 2026-05-22T20:30:00+00:00 Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.healthwireeasttimor.com/article/914437216-scynexis-announces-one-for-eight-reverse-stock-split Health Wire East Timor en PressRelease 2026-05-22T20:15:00+00:00 SCYNEXIS Announces One-for-Eight Reverse Stock Split https://ml.globenewswire.com/media/4171e010-3103-4d21-b1c5-5b1c27927dce/small/scyxprimarysmall-png.png https://www.healthwireeasttimor.com/article/914437253-nanobiotix-announces-full-exercise-of-underwriters-over-allotment-option-bringing-gross-proceeds-of-offering-to-approximately-100-million Health Wire East Timor en PressRelease 2026-05-22T20:15:00+00:00 NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914437258-nanobiotix-annonce-l-exercice-integral-de-l-option-de-surallocation-portant-le-produit-de-l-offre-a-100-millions-de-dollars Health Wire East Timor en PressRelease 2026-05-22T20:15:00+00:00 NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914437249-xtl-announces-receipt-of-staff-delist-determination-from-nasdaq Health Wire East Timor en PressRelease 2026-05-22T20:10:00+00:00 XTL Announces Receipt of Staff Delist Determination from Nasdaq https://ml.globenewswire.com/media/c90a3187-c398-47d6-a46e-5d3647374681/small/logo-png.png https://www.healthwireeasttimor.com/article/914437169-abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-trial-of Health Wire East Timor en PressRelease 2026-05-22T20:05:00+00:00 Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.healthwireeasttimor.com/article/914437171-abivax-pr-sente-ses-r-sultats-financiers-du-t1-2026-et-les-donn-es-trois-ans-de-l-tude-108-un-essai-d-extension-ouvert-de-phase-2a-2b-valuant Health Wire East Timor en PressRelease 2026-05-22T20:05:00+00:00 Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/ https://www.healthwireeasttimor.com/article/914437227-crinetics-pharmaceuticals-to-participate-in-jefferies-global-healthcare-conference-2026 Health Wire East Timor en PressRelease 2026-05-22T20:05:00+00:00 Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 https://ml.globenewswire.com/media/ff5e7cfa-b9fb-4679-8bf3-6e9d25207b83/small/crinetics-logo-trademark-jpg-1-jpg.jpg https://www.healthwireeasttimor.com/article/914437234-avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4 Health Wire East Timor en PressRelease 2026-05-22T20:01:00+00:00 Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/950a0fc1-6e06-40b5-9adc-6d3d9f2d5e78/small/avalo-final-black-01-jpg.jpg https://www.healthwireeasttimor.com/article/914427965-european-commission-grants-marketing-authorization-to-pharming-s-joenja-leniolisib-the-first-approved-treatment-for-apds-in-the-european-union Health Wire East Timor en PressRelease 2026-05-22T19:30:00+00:00 European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union https://ml-eu.globenewswire.com/media/f164672f-d67c-41d2-9c79-46caee419077/small/logo-pharming-original-png.png https://www.healthwireeasttimor.com/article/914401229-vaya-health-and-partners-health-management-announce-merger Health Wire East Timor en PressRelease 2026-05-22T17:30:00+00:00 Vaya Health and Partners Health Management Announce Merger https://ml.globenewswire.com/Resource/Download/362e27c4-b9da-40be-b326-0ea7fd8e2887/vaya-health.png https://www.healthwireeasttimor.com/article/914401048-scilex-holding-company-scilex-announces-its-board-of-directors-approved-a-dividend-of-semnur-pharmaceuticals-inc-common-stock-to-holders-of Health Wire East Timor en PressRelease 2026-05-22T17:15:00+00:00 Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026 https://ml.globenewswire.com/media/e2f985bf-0880-4d05-8838-90a69c888cf9/small/logo-jpg.jpg https://www.healthwireeasttimor.com/article/914392734-ai-saved-me-launches-to-document-how-people-are-using-ai-in-everyday-life Health Wire East Timor en PressRelease 2026-05-22T16:51:00+00:00 AI Saved Me Launches to Document How People Are Using AI in Everyday Life https://ml.globenewswire.com/media/b7b85bf8-8304-4292-ba08-61018931bc88/small/ai-saved-me-logo.png https://www.healthwireeasttimor.com/article/914392972-tpa-ncpa-applaud-tennessee-law-banning-pbms-from-owning-pharmacies Health Wire East Timor en PressRelease 2026-05-22T16:49:43+00:00 TPA, NCPA Applaud Tennessee Law Banning PBMs from Owning Pharmacies https://ml.globenewswire.com/media/MzA2OGM0OTgtNTM1OS00OGY2LWIzNTgtZTg3ZDRhOWRhY2FhLTExMzczNDEtMjAyNi0wNS0yMi1lbg==/tiny/National-Community-Pharmacists.png https://www.healthwireeasttimor.com/article/914393030-medx-holdings-announces-q1-2026-highlights-multi-city-expansion-and-corporate-action-to-rebrand-as-dazed-inc-ticker-daze Health Wire East Timor en PressRelease 2026-05-22T16:47:12+00:00 MEDX HOLDINGS ANNOUNCES Q1 2026 HIGHLIGHTS, MULTI-CITY EXPANSION, AND CORPORATE ACTION TO REBRAND AS DAZED INC. (TICKER: DAZE) https://ml.globenewswire.com/media/995733cb-620f-4ea6-b204-8b5b5689df30/small/medx-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914375548-the-newest-name-on-nasdaq-wants-to-help-the-body-rebuild-itself Health Wire East Timor en PressRelease 2026-05-22T15:30:00+00:00 The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself https://ml.globenewswire.com/media/537a8428-aa51-425e-b0c7-625da6b05a49/small/95686-jpg.jpg https://www.healthwireeasttimor.com/article/914359172-regenix-labs-introduces-nmn-supplement-designed-to-support-cellular-vitality-and-healthy-aging Health Wire East Timor en PressRelease 2026-05-22T14:00:00+00:00 Regenix Labs Introduces NMN Supplement Designed to Support Cellular Vitality and Healthy Aging https://ml.globenewswire.com/media/8d5a703e-01a1-4502-9218-3e6b056b489d/medium/regenix-labs-a-wellness-focused-company-committed-to-ingredi.png https://www.healthwireeasttimor.com/article/914350097-safespace-global-announces-new-senior-living-client-clearview-healthcare-management-expanding-deployment-across-seven-tennessee-facilities Health Wire East Timor en PressRelease 2026-05-22T13:15:00+00:00 SafeSpace Global Announces New Senior Living Client; Clearview Healthcare Management, Expanding Deployment Across Seven Tennessee Facilities https://ml.globenewswire.com/media/e95639ca-a47d-4c90-a44e-cf8a03b6a6d2/small/logo-jpg.jpg https://www.healthwireeasttimor.com/article/914350177-agios-pyrukynd-mitapivat-approved-in-the-european-union-for-adults-with-thalassemia Health Wire East Timor en PressRelease 2026-05-22T13:15:00+00:00 Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png https://www.healthwireeasttimor.com/article/914350118-oncolytics-biotech-to-present-data-at-asco-2026-reinforcing-pelareorep-s-potential-across-gastrointestinal-tumors Health Wire East Timor en PressRelease 2026-05-22T13:00:00+00:00 Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.healthwireeasttimor.com/article/914350127-bioage-labs-to-present-at-upcoming-investor-conferences Health Wire East Timor en PressRelease 2026-05-22T13:00:00+00:00 BioAge Labs to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.healthwireeasttimor.com/article/914341259-20-20-biolabs-commences-emergency-planning-for-ebola-hantavirus-lab-testing-if-outbreak-creates-overflow-demand Health Wire East Timor en PressRelease 2026-05-22T12:31:00+00:00 20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand https://ml.globenewswire.com/media/bcaf95ca-9983-408c-bc61-646e4ee2f925/small/2020-biolabs-logo-png.png https://www.healthwireeasttimor.com/article/914341214-fibrobiologics-presents-preclinical-data-demonstrating-durable-immunomodulation-in-psoriasis-at-the-society-for-investigative-dermatology-2026-annual Health Wire East Timor en PressRelease 2026-05-22T12:30:00+00:00 FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.healthwireeasttimor.com/article/914341294-ebola-outbreak-spreading-at-alarming-speed-who-warns-growing-global-health-emergencies-highlight-rising-need-for-tomi-s-steramist-technology Health Wire East Timor en PressRelease 2026-05-22T12:30:00+00:00 Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.healthwireeasttimor.com/article/914341229-chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu Health Wire East Timor en PressRelease 2026-05-22T12:15:00+00:00 CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.healthwireeasttimor.com/article/914331661-black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-conference Health Wire East Timor en PressRelease 2026-05-22T12:00:00+00:00 Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference https://ml.globenewswire.com/media/b8da4d92-789b-4f0a-a1e2-2739af370155/small/bdtxlogo-pantone3135c-png-png.png https://www.healthwireeasttimor.com/article/914331685-phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences Health Wire East Timor en PressRelease 2026-05-22T12:00:00+00:00 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/0baa6f51-c6cb-4b21-a4e0-573a18b8171c/small/phathom-pharm-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914331686-anavex-life-sciences-receives-expected-nasdaq-delinquency-notification Health Wire East Timor en PressRelease 2026-05-22T12:00:00+00:00 Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.healthwireeasttimor.com/article/914331787-sbc-medical-and-blez-asia-celebrate-opening-of-new-aesthetic-dermatology-section-at-blez-clinic-in-bangkok Health Wire East Timor en PressRelease 2026-05-22T12:00:00+00:00 SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok https://ml.globenewswire.com/media/67e1656f-882c-4c8e-bbb6-13bc2933e270/medium/sbc-medical-and-blez-asia-celebrate-opening-of-new-aesthetic.png https://www.healthwireeasttimor.com/article/914331792-2026-asco-pivotal-data-of-innocare-s-novel-bcl2-inhibitor-mesutoclax-released Health Wire East Timor en PressRelease 2026-05-22T12:00:00+00:00 2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released https://ml.globenewswire.com/media/2dc70b00-a0b0-4d85-adef-2717a7067aec/small/innocare-eng-logo-horizontal-png.png https://www.healthwireeasttimor.com/article/914331680-briacell-presentations-highlight-positive-clinical-data-for-bria-imt-at-asco-2026 Health Wire East Timor en PressRelease 2026-05-22T11:30:00+00:00 BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 https://ml.globenewswire.com/media/88b9408d-31d4-4afd-beff-f855719a15d8/small/briacell-logo-square-a-jpg.jpg https://www.healthwireeasttimor.com/article/914331684-repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-conference Health Wire East Timor en PressRelease 2026-05-22T11:30:00+00:00 Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://www.healthwireeasttimor.com/article/914322031-assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants Health Wire East Timor en PressRelease 2026-05-22T11:05:00+00:00 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/33089548-b62b-412d-9343-ae38d8b720c6/small/assemblybio-logo-rgb-png.png https://www.healthwireeasttimor.com/article/914321207-ac-immune-presents-new-phase-1-data-indicating-higher-uptake-of-tdp-43-pet-tracer-aci-19626-in-patients-with-als Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg https://www.healthwireeasttimor.com/article/914321585-cartigenix-hp-backed-by-three-human-studies-as-clinicians-seek-evidence-based-joint-health-options Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options https://ml.globenewswire.com/media/d7dc39f8-a2af-4bdc-8746-60a8c4c3ddc8/small/calroy-health-sciences-logo-rachel-rowley-png.png https://www.healthwireeasttimor.com/article/914321642-otarmeni-lunsotogene-parvec-receives-ema-filing-acceptance-for-genetic-hearing-loss Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914321718-enable-injections-announces-ce-certification-of-the-enfuse-on-body-delivery-system-for-use-with-aspaveli-distributed-by-sobi Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi https://ml.globenewswire.com/media/f41706a5-9f61-4772-83f1-6aa50c660788/small/enable-injections-logo-png.png https://www.healthwireeasttimor.com/article/914321794-biostem-technologies-announces-2-5-million-private-placement-financing-with-its-first-institutional-investor Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor https://ml.globenewswire.com/media/da0ea21a-fd6e-425a-a8f2-6f69dc2b4612/small/biostem-main-logo-png.png https://www.healthwireeasttimor.com/article/914321796-assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases https://ml.globenewswire.com/media/33089548-b62b-412d-9343-ae38d8b720c6/small/assemblybio-logo-rgb-png.png https://www.healthwireeasttimor.com/article/914321886-medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet Health Wire East Timor en PressRelease 2026-05-22T11:00:00+00:00 Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet https://ml.globenewswire.com/media/7e312e67-9924-4773-b548-47ed05d54904/small/new-logo-small-png.png https://www.healthwireeasttimor.com/article/914321869-arch-biopartners-announces-royal-columbian-hospital-has-dosed-its-first-patient-in-its-phase-ii-cardiac-surgery-associated-aki-trial Health Wire East Timor en PressRelease 2026-05-22T10:50:00+00:00 Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial https://ml.globenewswire.com/media/8fae7e83-0899-4bbc-ba40-0250cdb9aea7/small/logo-png.png https://www.healthwireeasttimor.com/article/914295860-biontech-pr-sentiert-auf-der-asco-jahrestagung-2026-fortschritte-aus-pipelineprogrammen-in-der-sp-ten-klinischen-entwicklung Health Wire East Timor en PressRelease 2026-05-22T09:00:00+00:00 BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.healthwireeasttimor.com/article/914295902-biontech-to-showcase-progress-across-late-stage-oncology-pipeline-at-the-2026-asco-annual-meeting Health Wire East Timor en PressRelease 2026-05-22T09:00:00+00:00 BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.healthwireeasttimor.com/article/914280549-china-approves-hernexeos-as-first-targeted-oral-treatment-option-for-her2-mutant-advanced-nsclc-at-initial-diagnosis Health Wire East Timor en PressRelease 2026-05-22T07:45:00+00:00 China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.healthwireeasttimor.com/article/914280532-storm-therapeutics-to-present-promising-phase-1-sarcoma-data-demonstrating-activity-of-first-in-class-mettl3-inhibitor-stc-15-at-asco-2026 Health Wire East Timor en PressRelease 2026-05-22T07:30:00+00:00 STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 https://ml-eu.globenewswire.com/media/1f159389-0c23-4305-b40e-b83e89274cee/small/logo-png.PNG https://www.healthwireeasttimor.com/article/914264116-hanmi-pharmaceutical-se-asocia-con-organon-para-exportar-terapias-combinadas-al-sudeste-asi-tico Health Wire East Timor en PressRelease 2026-05-22T06:20:18+00:00 Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático https://ml.globenewswire.com/media/526a18fe-e048-4862-91e5-0a6effeaf8ab/small/hanmi-pharmaceutical-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914264215-hanmi-pharmaceutical-faz-parceria-com-a-organon-para-exporta-o-de-terapias-de-combina-o-para-o-sudeste-asi-tico Health Wire East Timor en PressRelease 2026-05-22T06:20:18+00:00 Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático https://ml.globenewswire.com/media/526a18fe-e048-4862-91e5-0a6effeaf8ab/small/hanmi-pharmaceutical-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914264043-angel-introduces-x2-water-filter-system-with-advanced-tankless-7-stage-filtration-and-99-pfas-reduction Health Wire East Timor en PressRelease 2026-05-22T05:45:33+00:00 ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction https://ml.globenewswire.com/media/38ebd348-2161-4e2e-bd81-b7e8c6fd5324/medium/image-1.jpeg https://www.healthwireeasttimor.com/article/914263955-ose-immunotherapeutics-annonce-les-r-sultats-de-topline-positifs-de-l-tude-de-phase-2-tedova-de-tedopi-dans-le-cancer-de-l-ovaire-en-rechute Health Wire East Timor en PressRelease 2026-05-22T05:30:00+00:00 OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.healthwireeasttimor.com/article/914263967-ose-immunotherapeutics-reports-positive-topline-results-of-tedova-phase-2-trial-with-tedopi-in-recurrent-ovarian-cancer Health Wire East Timor en PressRelease 2026-05-22T05:30:00+00:00 OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.healthwireeasttimor.com/article/914242935-nervgen-announces-pricing-of-us-60-0-million-public-offering-of-securities Health Wire East Timor en PressRelease 2026-05-22T03:27:00+00:00 NervGen Announces Pricing of US$60.0 Million Public Offering of Securities https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.healthwireeasttimor.com/article/914218852-medline-inc-announces-pricing-of-upsized-secondary-offering-of-class-a-common-stock Health Wire East Timor en PressRelease 2026-05-22T02:45:00+00:00 Medline Inc. announces pricing of upsized secondary offering of Class A common stock https://ml.globenewswire.com/media/70e45830-32e3-4232-b15b-7e43c436de41/small/log-medline-1200-630-center-png.png https://www.healthwireeasttimor.com/article/914218482-femicore-claims-evaluated-investigating-the-ingredients-for-bladder-support-femi-core-consumer-complaints-exposed Health Wire East Timor en PressRelease 2026-05-22T01:24:10+00:00 FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed https://zingfast.com/wp-content/uploads/2026/05/FemiCore.jpg https://www.healthwireeasttimor.com/article/914218418-most-effective-magnesium-pain-cream-researched-real-magnesium-niacinamide-relief-for-peak-health-nerve-pain-recovery Health Wire East Timor en PressRelease 2026-05-22T01:05:27+00:00 Most Effective Magnesium Pain Cream Researched: Real Magnesium Niacinamide Relief for Peak Health & Nerve Pain Recovery https://zingfast.com/wp-content/uploads/2026/05/Best-Magnesium-Pain-Cream.jpg https://www.healthwireeasttimor.com/article/914190921-liminatus-pharma-announces-nasdaq-delisting-notification Health Wire East Timor en PressRelease 2026-05-22T00:28:26+00:00 Liminatus Pharma Announces Nasdaq Delisting Notification https://ml.globenewswire.com/media/9ad52a99-f6dd-4ecb-8aa0-15713a0e8788/small/picture1-png.png https://www.healthwireeasttimor.com/article/914190534-taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-in-hiv-maintenance-therapy-study Health Wire East Timor en PressRelease 2026-05-22T00:00:00+00:00 TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study https://ml.globenewswire.com/media/1cb82885-f089-49cf-9399-8f9e4bc0918c/small/taimed-logo-png.png https://www.healthwireeasttimor.com/article/914190829-hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting Health Wire East Timor en PressRelease 2026-05-22T00:00:00+00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/085957ad-3bec-49ee-b13e-39961b83c7be/small/hutchmed-small-spaced-1000x305-whitebgd-png.png https://www.healthwireeasttimor.com/article/914190865-ascentage-pharma-releases-latest-clinical-data-from-multiple-trials-at-asco-2026 Health Wire East Timor en PressRelease 2026-05-22T00:00:00+00:00 Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 https://ml.globenewswire.com/media/b9623a51-a13b-4b80-8152-61d5014f4a0a/small/2025-11-12-ascentage-600x600-png.png https://www.healthwireeasttimor.com/article/914163533-fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmark-at-the-2026-asco-annual-meeting Health Wire East Timor en PressRelease 2026-05-21T22:01:27+00:00 Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/2eeb9b85-0beb-4bbe-a7af-1c0e9403db44/small/fennec-logo-png.png https://www.healthwireeasttimor.com/article/914163048-biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122-dnl151-in-early-stage-parkinson-s-disease Health Wire East Timor en PressRelease 2026-05-21T22:00:00+00:00 Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg https://www.healthwireeasttimor.com/article/914163509-biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122-dnl151-in-early-stage-parkinson-s-disease Health Wire East Timor en PressRelease 2026-05-21T22:00:00+00:00 Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease https://ml.globenewswire.com/media/898f19a9-f6ef-4d5a-8a4f-27709b81609a/small/denali-green-logo-png.png https://www.healthwireeasttimor.com/article/914163052-perspective-therapeutics-to-present-data-from-all-clinical-programs-at-the-2026-asco-annual-meeting-including-findings-from-212pb-vmt01-in-melanoma Health Wire East Timor en PressRelease 2026-05-21T21:51:13+00:00 Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma https://ml.globenewswire.com/media/e8b42463-3d31-441e-8c09-6b88826fe1c6/small/persp-jpg.jpg https://www.healthwireeasttimor.com/article/914162936-zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-clinical-activity-and-manageable-safety-profile-of-azenosertib-plus Health Wire East Timor en PressRelease 2026-05-21T21:39:11+00:00 Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 https://ml.globenewswire.com/media/ecb98bea-7a9f-4319-874c-1911777a5a46/small/zentalis-logo-full-color-png.png https://www.healthwireeasttimor.com/article/914162553-crescent-biopharma-announces-trial-in-progress-presentation-for-ascend-study-of-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-upcoming-american Health Wire East Timor en PressRelease 2026-05-21T21:30:00+00:00 Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting https://ml.globenewswire.com/media/57dabf2a-90a3-4786-9c39-d1e71cc7707f/small/crescent-biopharma-logo-color-png.png https://www.healthwireeasttimor.com/article/914163191-pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting Health Wire East Timor en PressRelease 2026-05-21T21:29:30+00:00 Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting https://ml.globenewswire.com/media/6a9e3f3f-d4fb-4bf0-9480-3bbd3fd2ced9/small/pliant-logo-300x300-jpg.jpg https://www.healthwireeasttimor.com/article/914162947-aktis-oncology-reports-first-in-human-clinical-imaging-and-dosimetry-data-for-aky-2519-demonstrating-robust-tumor-uptake-and-limited-normal-tissue Health Wire East Timor en PressRelease 2026-05-21T21:21:08+00:00 Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.healthwireeasttimor.com/article/914162745-jupiter-neurosciences-announces-closing-of-2-0-million-registered-direct-offering Health Wire East Timor en PressRelease 2026-05-21T21:15:00+00:00 Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering https://ml.globenewswire.com/media/4e829d7e-ecf6-46ad-98fe-479755d626e1/small/image-png.png https://www.healthwireeasttimor.com/article/914162747-black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations Health Wire East Timor en PressRelease 2026-05-21T21:13:52+00:00 Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations https://ml.globenewswire.com/media/b8da4d92-789b-4f0a-a1e2-2739af370155/small/bdtxlogo-pantone3135c-png-png.png https://www.healthwireeasttimor.com/article/914159935-autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026 Health Wire East Timor en PressRelease 2026-05-21T21:10:00+00:00 Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 https://ml.globenewswire.com/media/680b5e1a-9aba-4e38-b280-e43036561ef1/small/picture1-png.png https://www.healthwireeasttimor.com/article/914159924-remix-therapeutics-announces-positive-data-from-phase-1-2-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic Health Wire East Timor en PressRelease 2026-05-21T21:05:00+00:00 Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026 https://ml.globenewswire.com/media/4facea87-f600-4440-a295-a31bb083c9bd/small/remix-logo-png.png https://www.healthwireeasttimor.com/article/914162229-eikon-therapeutics-announces-availability-of-six-abstracts-for-presentation-at-the-2026-annual-meeting-of-the-american-society-of-clinical-oncology Health Wire East Timor en PressRelease 2026-05-21T21:05:00+00:00 Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology https://ml.globenewswire.com/media/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9/small/eikon-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914162615-moleculin-highlights-abstract-accepted-for-poster-presentation-at-the-2026-asco-annual-meeting-highlighting-cardiac-safety-data-for-annamycin Health Wire East Timor en PressRelease 2026-05-21T21:02:00+00:00 Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png https://www.healthwireeasttimor.com/article/914162250-lynozyfic-linvoseltamab-monotherapy-demonstrates-deep-and-rapid-responses-in-all-treated-patients-with-second-line-plus-systemic-amyloid-light Health Wire East Timor en PressRelease 2026-05-21T21:01:52+00:00 Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914160115-syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data Health Wire East Timor en PressRelease 2026-05-21T21:01:00+00:00 Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data https://ml.globenewswire.com/media/399a65b5-bd4f-4ba5-980b-f4d0af9ae6a0/small/syndax-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914161874-akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated Health Wire East Timor en PressRelease 2026-05-21T21:01:00+00:00 Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://www.healthwireeasttimor.com/article/914159763-boehringer-ingelheim-s-oncology-portfolio-shows-strong-promise-across-multiple-cancers-at-asco-2026 Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026 https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.healthwireeasttimor.com/article/914160133-legend-biotech-announces-presentations-at-asco-2026 Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Legend Biotech Announces Presentations at ASCO 2026 https://ml.globenewswire.com/media/d3a680c2-cab6-4eb2-9ed0-7be055f9e180/small/legend-logo-fullcolor-transparent-1-png.png https://www.healthwireeasttimor.com/article/914160307-cardiff-oncology-announces-webcast-to-discuss-updated-phase-2-crdf-004-data-for-onvansertib-in-first-line-ras-mutated-mcrc Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC https://ml.globenewswire.com/media/916adb81-8173-4fbe-8095-c284c4f44cd3/small/cardiff-jpg.jpg https://www.healthwireeasttimor.com/article/914160452-olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://www.healthwireeasttimor.com/article/914161079-compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in-patients-with-advanced-malignancies-treated-in-the-post-checkpoint Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.healthwireeasttimor.com/article/914161304-ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated-three-year-overall-survival-and-deep-responses-driven-by-tgf-inhibition-in-1l-r-m Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.healthwireeasttimor.com/article/914161429-immuneering-reports-17-3-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://www.healthwireeasttimor.com/article/914161439-blossomhill-therapeutics-to-present-preliminary-results-from-phase-1-dose-escalation-backfill-cohorts-in-phase-1-2-solara-trial-of-omni-egfr Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/02f747e9-636d-467e-81f8-d942e9421158/small/blossomhill-vertical-fullcolor-cmyk1-jpg.jpg https://www.healthwireeasttimor.com/article/914161460-rgenta-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-1a-b-clinical-trial-of-rgt-61159-in-patients-with-adenoid-cystic-carcinoma Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting https://ml.globenewswire.com/media/de2f6450-22c4-4c16-b785-04cea917de03/small/rgenta-logo-fullcolor-print-1-png.png https://www.healthwireeasttimor.com/article/914161474-asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline https://ml.globenewswire.com/media/3b2f30c8-cc67-45e5-a0d5-27b5e2c43de8/small/asher-bio-logo-rgb-large-png.png https://www.healthwireeasttimor.com/article/914162207-hibercell-to-present-preliminary-results-from-the-phase-1b-trial-of-gcn2-activator-hc-7366-when-combined-with-welireg-belzutifan-for-the-treatment Health Wire East Timor en PressRelease 2026-05-21T21:00:00+00:00 HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/d168805a-8691-40f2-abcf-fb63a607f112/small/hybercell-jpg.jpg https://www.healthwireeasttimor.com/article/914162080-seer-board-of-directors-unanimously-rejects-further-revised-unsolicited-proposal-from-radoff-jec-group Health Wire East Timor en PressRelease 2026-05-21T20:38:38+00:00 Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group https://ml.globenewswire.com/media/a5aaadad-13a1-4dbd-8ba2-d57cbbc610fb/small/seer-brandmark-rgb-full-jpg.jpg https://www.healthwireeasttimor.com/article/914131867-mental-health-care-in-utah-gets-major-boost-with-new-behavioral-health-center-at-intermountain-health-alta-view-hospital Health Wire East Timor en PressRelease 2026-05-21T20:30:03+00:00 Mental Health Care in Utah Gets Major Boost with New Behavioral Health Center at Intermountain Health Alta View Hospital https://ml.globenewswire.com/media/M2RhNGQ2MzYtOGQxZC00Njg5LTkzYWMtOTYzMzFmZGUyYThiLTEyNjkxMjYtMjAyNi0wNS0yMS1lbg==/tiny/Intermountain-Health.png https://www.healthwireeasttimor.com/article/914131634-adaptive-biotechnologies-to-participate-in-upcoming-investor-conferences Health Wire East Timor en PressRelease 2026-05-21T20:17:30+00:00 Adaptive Biotechnologies to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/6c319974-0bac-45f1-83d9-ae9987dfdf44/small/adpt-new-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914128710-first-tracks-biotherapeutics-announces-participation-in-upcoming-investor-conferences Health Wire East Timor en PressRelease 2026-05-21T20:15:00+00:00 First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences https://ml.globenewswire.com/media/7165e7cf-d98b-4a0f-90f3-3cd8f3a6b320/small/ftb-logo-png.png https://www.healthwireeasttimor.com/article/914131141-lunavelle-sleep-patches-claims-evaluated-most-effective-melatonin-free-patches-for-deeper-rest-with-time-tested-ingredients-proven-to-work Health Wire East Timor en PressRelease 2026-05-21T20:05:36+00:00 Lunavelle Sleep Patches Claims Evaluated: Most Effective Melatonin-Free Patches for Deeper Rest with Time-Tested Ingredients Proven To Work https://zingfast.com/wp-content/uploads/2026/05/Lunavelle-Sleep-Patches.jpg https://www.healthwireeasttimor.com/article/914127952-pacbio-to-participate-in-the-jefferies-global-healthcare-conference Health Wire East Timor en PressRelease 2026-05-21T20:05:00+00:00 PacBio to Participate in the Jefferies Global Healthcare Conference  https://ml.globenewswire.com/media/f408d681-e68c-4113-a7cd-be24486deefc/small/logo-centered-440x386-png.png https://www.healthwireeasttimor.com/article/914128623-outset-medical-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Health Wire East Timor en PressRelease 2026-05-21T20:05:00+00:00 Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/28778c78-03f1-4b17-9c13-3cc578c924dc/small/outset-id-orangegrey-png.png https://www.healthwireeasttimor.com/article/914128819-revolution-medicines-to-host-investor-conference-call-on-positive-rasolute-302-results-following-2026-asco-presentation Health Wire East Timor en PressRelease 2026-05-21T20:05:00+00:00 Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.healthwireeasttimor.com/article/914128898-madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4 Health Wire East Timor en PressRelease 2026-05-21T20:05:00+00:00 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8fec8de1-1a2e-4f6c-a679-fc43002276ba/small/madrigal-logo-jpg.jpg https://www.healthwireeasttimor.com/article/914129096-camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Health Wire East Timor en PressRelease 2026-05-21T20:05:00+00:00 CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/72048fc6-0a8d-4ed2-9be8-ec0ee0afd8ba/small/cmp4-21-logo-full-color-jpg.jpg https://www.healthwireeasttimor.com/article/914129173-cue-biopharma-to-present-at-the-2026-jefferies-global-healthcare-conference Health Wire East Timor en PressRelease 2026-05-21T20:05:00+00:00 Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference https://ml.globenewswire.com/media/10541379-34cc-4869-a26f-fd99feead42a/small/cue-bio-brand-strategy-graphics-jpg.jpg https://www.healthwireeasttimor.com/article/914130503-beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development Health Wire East Timor en PressRelease 2026-05-21T20:04:00+00:00 Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development https://ml.globenewswire.com/media/dd9f136d-aea8-46b4-8bfa-63568d4bc933/medium/mint-by-beta-bionics.jpg https://www.healthwireeasttimor.com/article/914130694-nervgen-announces-proposed-public-offering-of-securities Health Wire East Timor en PressRelease 2026-05-21T20:01:00+00:00 NervGen Announces Proposed Public Offering of Securities https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.healthwireeasttimor.com/article/914127350-inventiva-to-present-at-2026-jefferies-global-healthcare-conference Health Wire East Timor en PressRelease 2026-05-21T20:00:00+00:00 Inventiva to Present at 2026 Jefferies Global Healthcare Conference   https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/logo-iva-jpg.jpg https://www.healthwireeasttimor.com/article/914127354-inventiva-pr-sentera-lors-de-la-2026-jefferies-global-healthcare-conference Health Wire East Timor en PressRelease 2026-05-21T20:00:00+00:00 Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/ https://www.healthwireeasttimor.com/article/914127557-oddifact-obtient-la-d-signation-m-dicament-orphelin-de-la-commission-europ-enne-pour-l-infliximab-dans-la-maladie-de-kawasaki Health Wire East Timor en PressRelease 2026-05-21T18:50:22+00:00 ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki https://ml-eu.globenewswire.com/media/e678baea-021e-47f5-9676-4ef415772a73/small/ https://www.healthwireeasttimor.com/article/914127755-oddifact-receives-european-commission-orphan-drug-designation-for-infliximab-in-kawasaki-disease Health Wire East Timor en PressRelease 2026-05-21T18:50:22+00:00 ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease https://ml-eu.globenewswire.com/media/e678baea-021e-47f5-9676-4ef415772a73/small/logo-oddifact-png.png https://www.healthwireeasttimor.com/article/914098116-bulkglp-announces-dual-tier-quality-verification-protocol-for-global-supply-of-analytical-reference-materials Health Wire East Timor en PressRelease 2026-05-21T17:51:44+00:00 BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials https://ml.globenewswire.com/media/d8909950-3310-4178-9552-aa9f02c08d58/medium/bulkglp-logo.png https://www.healthwireeasttimor.com/article/914097996-nmdp-gala-in-new-york-city-raises-record-breaking-660-000-enabling-more-patients-to-receive-life-saving-cell-therapy Health Wire East Timor en PressRelease 2026-05-21T17:27:28+00:00 NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy https://ml.globenewswire.com/media/07439704-ea73-4f29-9900-95a8261e9c45/medium/nmdp-gala-nyc-2026.jpg